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Abstrak  
“Mooren’s Ulcer” adalah ulkus kornea yang bersifat progresif, nyeri, 
sering berulang sedangkan penyebabnya tidak diketahui. Pada tulisan ini 
dilaporkan kegunaan tindakan operasi “Bare Sclera conjunctival resection” 
dengan pemasangan MLAMT pada ulkus Mooren yang diikuti dengan penutupan 
mata selama 3 hari berturut turut. Pada pasien ini dikerjakan 3 kali operasi yang 
sama.   Kasus adalah seorang wanita berumur 45 tahun dengan Ulkus Mooren 
yang sudah berulang di pinggir kornea didaerah flap konyungtifa  pada mata 
kanannya sedangkan mata kiri dengan “pthysis bulbi”. Visus mata kanan 20/25, 
mata kiri Nol, pemeriksaan laboratorium normal, saat ini pasien menolak untuk 
dilakukan operasi. Pasien datang 1 bulan kemudian dengan keadaan yang lebih 
buruk, dan setuju  dioperasi, dilakukan Partial Bare Sclera conjunctival resection 
dengan MLAMT, pada hari kesembilan setelah operasi sudah terjadi epitelisasi 
komplit. Empat bulan kemudian ulkus korneanya meluas keparasentral dan 
superior kornea yang cendrung perforasi, dilakukan operasi kedua dengan tehnik 
yng sama. Ternyata epitelisasi kornea baru komplit pada hari ketigabelas. Hal 
yang sangat jelek adalah ditemukan lagi ulkus baru dibagian bawah kornea, 
sehingga diputuskan untuk langsung melakukan Total Bare Sclera conjunctival 
resection dan MLAMT, Epitelisasi komplit pada ulkus terjadi pada hari 
kesembilan. Pengobatan setelah operasi antibiotik tetes mata dan kortikosteroid 
secara sistemik. Visus mata kanan saat ini 20/40. Dapat disimpulkan bahwa Ulkus 
Mooren merupakan ulkus kornea yang progresif, dengan transplantasi membrane 
Amnion dan Bare Sclera dapat memperlama munculnya rekurensi tapi tidak 
menyembuhkannya. 
Kata kunci: MLAMT, Bare Sclera, Mooren’s ulcer 
 
 
Abstract 
Mooren’s Ulcer is a progressive, pain corneal disease, which is difficult to 
be treated with unknown etiology. This Interventional Case Report is aimed at 
reporting the efficacy of Bare Sclera and (MLAMT) with three days patching for 
recurrent Mooren’s Ulcer. 
LAPORAN KASUS 
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We performed three times Bare Sclera conjunctiva resection with MLAMT on one 
case of recurrent Mooren’s ulcer. Fourty five years old female with Recurrent 
Mooren’s ulcer on the right eye, at margin of the conjunctival flap and pthysis 
bulbi on the left eye. Visual acuity (VA) on the right eye was 20/25. Normal 
laboratory examinations. In this condition she did not agree for operation. One 
month later, with worse condition, and we performed partial Bare Sclera with 
MLAMT. After surgery, the epithelialization was completes on the ninth day. 
Four months later, the active ulcer was extended to paracentral and superior 
cornea with impending perforatian. We did second surgery, partial Bare Sclera 
with MLAMT. After surgery, the epithelialization was completes on the thirteenth 
day. Unfortunately, we found the new ulcer on the inferior cornea, and then we 
decided to perform the third surgery, total Bare Sclera and MLAMT, the 
epithelialization was completes on the ninth day. Post operation, topical antibiotic 
and systemic corticosteroid. The VA on the right eye was 20/40. 
We conclude that, Mooren’s ulcer is a progressive corneal disease. Although only 
one case being reported, MLAMT can reduce the recurrence duration of Mooren’s 
ulcer, but cannot stop the progressivity. MLAMT could be performed more than 
once. Total conjunctiva resection can make epithelialization significantly faster 
than partial resection. 
Keywords: MLAMT, Bare Sclera, Mooren’s ulcer 
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Introduction 
Mooren’s ulcer was first 
described by Bowman in 1849 and 
McKenzie in 1854 as ‘chronic 
serpiginous ulcer of the cornea or 
ulcus rodens’. However, Mooren who 
was the first to publish several cases on 
this condition in 1867 and also the first 
to clearly describe this corneal 
condition and define it as a clinical 
entity.
(1)
 
Mooren’s ulcer is an idiopathic, 
painful, relentlessly progressive 
chronic ulcerative keratitis that begins 
as grayish infiltrations,
(2)
 as a crescent-
shaped gray-white infiltrate in the 
perilimbal cornea, usually in the 
interpalpebral fissures.
(3)
 Its most 
unique clinical characteristics include 
the “eating away” of cornea central to 
the most obvious crescent of epithelial 
defect and stromal melting,
 
the process 
eventually undermines the central wall 
of the thinned tissue, leading to 
characteristic “overhanging” central 
edge.
(2,3)
 It’s progresses 
circumferentially and centrally, some 
times progressing to full corneal 
thickness and perforation. Srinivasan et 
al,
(4)
 were reported that in patients with 
total corneal involvement, the corneal 
stroma was replaced by fibro vascular 
scar covering an intact Descemet’s 
membrane. Although spontaneous 
perforation is uncommon, these eyes 
are characteristically quite vulnerable 
toward perforation with minimal 
trauma. The ulcer usually responds 
poorly to conventional therapy, 
occurring in the complete absence of 
any diagnosable systemic disorder that 
could be responsible for the 
progressive destruction of the cornea.
(1-
3)
  
Wood and Kaufman classified 
the disease into two groups according 
to the age of onset, clinical 
characteristics, and prognosis. Type I 
was benign and usually unilateral with 
mild to moderate symptoms, occurs in 
old people over 35 years, usually well 
responded to medical and surgical 
treatments. The second type was more 
likely to be bilateral with relative more 
pain and generally a poor response to 
the therapy occurs in young patients 
younger than 35 years. Watson divided 
the disease into three types, unilateral 
Mooren’s ulcer, bilateral aggressive 
Mooren’s ulcer, and bilateral indolent 
Mooren’s ulcer.(1-3) 
 
Pathogenesis 
Mooren’s Ulcer is one 
differential diagnosis of peripheral 
ulcerative keratitis (PUK), involvement 
of the limbus, begins as grayish 
infiltrations in the perilimbal cornea, 
there is no clear zone (lucid interval)
(1)
 
between the ulcer and the limbus. The 
central margin of the ulcer has an 
overhanging edge, without associated 
with necrotizing scleritis, and many of 
the collagen vascular diseases.  In very 
severe cases, episcleritis or even 
scleritis may be present,
(5) 
the exact 
patophysiology remains uncertain and 
recent study indicates that it is an 
autoimmune process, with both cell-
mediated and humoral components. On 
pathological examination, plasma cells, 
neutrophils, mast cells and eosinophils 
have been found in the adjacent 
conjunctiva. In the involved areas, 
Brown
in1 
has demonstrated the high 
levels of proteolysis enzymes and they 
found that numerous active neutrophils 
were the source of the proteases and 
collagenases that degrade the corneal 
stroma. 
A deficiency of suppressor T 
cells was found in the serum of patient 
with Mooren’s ulcer. The ratio of 
helper T cell/suppressor T cell greater 
than 1/1.
(3) 
The unregulated helper T 
cells overproduce antibodies, resulting 
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in the deposition of immune 
complexes, complement activation, 
inflammatory cell infiltration, and 
proteolysis enzyme release in Morren’s 
ulcer. 
Gottsch et al (1995),
(6)
 
Bielinska A et al (2006),
(7)
 found that a 
great role play for pathogenesis in 
Mooren’s ulcer, probably reaction of 
auto antibodies against to Cornea-
Associated Stromal Antigen (CO-Ag). 
This antigen has appeared to be similar 
to calgranulin C, which found in 
circulating leucocytes,
(8)
 and the 
protein binding Ca 
2+
 fixed on the 
surface of the helminthes.
(8) 
Taylor et al (2000),
(8)
 Zelefsky 
JR et al (2007),
(9)
 had been reported a 
possible association between HLA-
DR17
 
and/or DQ2 susceptibility to 
Mooren’s ulcer. Liang CK et al 
(2002),
(10)
 also reported about HLA-
DR17 and HLA-DQ2 and suggested 
HLA-DQ5 might be another candidate 
gene of HLA associated with Mooren’s 
ulcer. This is why the 
immunosuppressive therapy has been 
shown to be increasingly successful in 
patient who is unresponsive to 
conventional treatment.
(1) 
Advances 
have been made for better 
understanding of the etiopathogenesis 
and for the management of this 
disorder, but a significant percentage of 
cases remain refractory to available 
therapies and results in severe visual 
morbidity. 
Infectious associations have 
been reported with helminthiasis and 
hepatitis C. Schanzlin
in1
, speculated 
that the antigen antibody reaction to 
helminth toxins deposited in the 
peripheral cornea provokes the 
inflammation and ulceration. Wilson 
SE et al(1993),
(11)
 Baratz KH et al 
(1998),
(12)
 proposed that molecular 
mimicry maybe involved, with the 
hepatitis C virus stimulating an 
autoimmune in response to corneal 
antigens through cross-reacting 
epitopes. Alternatively, they also 
proposed that deposition of immune 
complexes in limbal or peripheral 
corneal tissues may lead to an immune 
response and release of proteolysis 
enzymes.
 
Other infections that have 
been associated with Mooren’s ulcer 
include herpes simplex and zoster, 
syphilis, tuberculosis, and there are 
also other associations reported with 
physical trauma, foreign body, 
chemical burn, and may recurred after 
surgical procedure such as cataract 
extraction and penetrating 
keratoplasty.
(1,2) 
Touge et al (2004),
(13)
 found in 
their case, that Mooren’s ulcer occurred 
solely at the head of a pterygium. On 
their observed, they found the 
infiltration of lymphocytes in the body 
of the pterygium, and in the ulcer area, 
there was irregular proliveration of the 
corneal epithelium and infiltration of 
numerous neutrophils and lymphocytes 
under the corneal epithelium. Both T 
and B cells were infiltrated into the 
pterygium body and ulcer area, and T 
cells especially were more abundant in 
the ulcer area than in the pterygium 
body.  
 
Treatment 
The initial medical therapy for 
Mooren’s ulcer include, aggressive 
steroid topical eye drops such as 
prednisolone acetate or phosphate 1%, 
hourly (or every half hour),
(14)
 
cycloplegics eye drops and 
prophylactic antibiotics.
 
If 
epithelialization occurs, topical steroids 
can be tapered slowly over several 
months, we must be aware in used 
intensive corticosteroid topical, it can 
be delayed of epithelial wound healing 
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and impends corneal perforation, in this 
case we can consider to changes with 
systemic corticosteroid.
(14)
 Topical 
tetracycline or medroxyprogesterone 
can be used for anticollagenolytic 
properties and therapeutic soft contact 
lens or patching of the eye for rapid 
epithelialization and reduces corneal 
pain.  
The use of topical and systemic 
immunosuppressive chemotherapy; 
cyclophosphamide (3mg/kg/day), 
metho-trexate (7,5 to 25 mg/week) and 
azathioprine (3mg/kg/day),
(1) 
cyclophos-phamide may be effective 
by suppressing B-lymphocytes, which 
produce autoantibodies and promote 
immune complex disease. 
Cyclosporine-A systemic 3-4 
mg/kg/day and topical 0,05%, 0,1%,
(15)
 
0,2%, may work by suppression of the 
helper T-cells population and 
stimulation of the depressed population 
of cytotoxic T-cells, has been 
successfully used to treat Mooren’s 
ulcer.  
Erdem U et al (2006),
(16)
 
reported the beneficial effect of topical 
Interferon Alfa 2a (1 million 
international units per milliliter, were 
prepared via dilution of the injectable 
recombinant IFNα2a with preservative-
free balanced salt solution) for 2 
patients with unilateral Mooren’s ulcer. 
The diagnosis of Mooren’s ulcer was 
made based on clinical presentation, 
negative laboratory work up for 
underlying diseases and the antibodies 
against herpes simplex virus, herpes 
zoster virus, toxoplasma,  hepatitis B 
and C viruses were not detected in the 
serum patients. The corneal cultures for 
possible infective agents were negative 
too.  
Fontana L et al (2007),
(17)
 
reported their case about using of 
infliximab, an anti-tumour necrosis 
factor agent, for the treatment of one 
patient with progressive bilateral 
Mooren’s ulcer developed recurrent 
corneal perforations and melting, 
requiring tectonic grafts. The patient 
had been treated with conventional 
triple oral immunosuppression 
(Azathioprine, and then Cyclosporin A 
coupled with Metotrexate) during 2 
years. Before that, the patient also was 
treated by conjunctival resection, 
corneal gluing and oral prednisone. The 
reduction of conjunctival injection was 
observed soon after the first infliximab 
infusions and no recurrence of 
ulcerations and perforations during a 
follow up of 2 years. No significant 
side effects occurred during treatment.  
Conjunctival resection and 
excision (Bare sclera) was shown to be 
an effective temporary surgical 
treatment for Mooren’s ulcers because 
it decreases the exposure of corneal 
stromal antigen by systemic 
circulation. The resection should 
extend 3 to 4 mm posterior to the 
limbus and well beyond the edge of the 
affected area,
(18)
 and the recommended 
area of conjunctival excision includes 1 
clock hour on the either side of the 
ulceration.
(19)
 the operation can follow 
with used Amnion Membrane 
Transplantation for faster recovery and 
minimal cicatrices after operation. 
Human Amniotic Membrane 
(HAM) is the innermost of the three 
layers forming the fetal membranes; it 
is a biological tissue that has been used 
as graft for corneal and conjunctiva 
reconstruction in a variety of ocular 
surface diseases. The first use of 
HAMT in ophthalmology was by De 
Rotth in 1940; follow by Sorsby and 
Symons 1946, Kim and Tseng 1994.
(20)
 
It is avascular and possesses 
antiangiogenic, to facilitate ocular 
surface healing with minimal 
inflammation and scaring, 
antimicrobial, non-immunogenic, anti 
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inflammatory properties and reduces of 
corneal pain. It is not a substitution but 
rather a substrate upon which cells can 
migrate and regenerate, promote 
epithelial differentiation, reinforce 
adhesion of the epithelial cells, and 
prevent epithelial cell apoptosis or 
programmed cell death.
(21,22) 
The AM 
used as a biologic patch, as a bandage, 
to treat corneal and conjunctiva 
inflammation to forming new and 
healthy tissues.
(21,22)
 
The MLAMT is useful in 
corneal ulceration and corneal 
perforation, the success rate of 72% 
compare 64% with monolayer. 
Reported by Lee SH et al (1966),
(23)
 
Kruse et al (1999),
(24)
 Hanada et al 
(2001),
(25)
 Prabhasawat et al (2001),
(26) 
Sukmawati (2006),
(27)
 the multilayered 
AMT have been successful because the 
monolayer AMT disappears within a 
few weeks. Solomon et al (2001),
(28)
 
reported a success result in 82.3% in 
multilayered AMT and, by using 
multilayered the corneal defect healed 
significantly faster than a single layer.  
The Amnion Membrane use in 
this case is The Freeze-Dried (FDAM) 
prepared by The M. Djamil Hospital 
Tissue Bank (West Sumatera, 
Indonesia) has a Standard Operating 
Procedure from International Atomic 
Energy Agency (IAEA), to assure the 
quality of the lyophilisation and 
radiation sterilization.
(29)
 
 
Case Report  
We reported one patient, 45 
years old female with Mooren’s ulcer 
on the right eye and pthysis bulbi on 
the left eye. The diagnosis based on the 
clinical characteristic and negative 
laboratory work up for rheumatologic, 
hepatitis, helminthes, allergic and 
negative scraping and culture infectious 
causes of PUK. Visual acuity of the 
right eye was 20/25 and there was no 
history of the left eye. On the right eye, 
we found conjunctivalization with 
corneal thinning and excavation on the 
margin of the conjunctival flap on the 
temporal side, its size about 5x1mm, 
the depth up to 2/3 the stromal cornea, 
from 7
oo
 to 11
oo
 clock and cicatrices on 
the nasal side about 4x3 mm. 
Unfortunately, this patient with history 
of conjunctival flap to protect corneal 
perforation. (See photos on August 06). 
At this time, we suggest to 
perforrm operation for Bare Sclera 
(resection of conjunctiva) with Multi 
Layer Amniotic Membrane 
Transplantation (MLAMT), but she did 
not agree. So we only gave medications 
i.e. topical antibiotic, lubrication, 
topical and systemic anti collagenase, 
systemic anti glaucoma and 
multivitamins for epithelialization. We 
did not give topical corticosteroid 
because impending perforation and 
risky case (one eyed) and cyclosporine 
(no available preparation). 
One month later (See photos on 
September 2006), she admitted to our 
hospital with worse condition, the 
recurrent Mooren’s ulcer is deeper, 
extended to paracentral cornea and she 
was agree for the operation. We 
performed partial Bare Sclera and 
MLAMT with three days patching, 
under general anesthesia and informed 
concern was done before that. On the 
fifth day after the operation, the 
epitelialization begins to cover the thin 
corneal and on the ninth day 
epitelialization was completes 
(fluorescents staining was negative), 
but the thinner corneal surface that 
covered by the thin amnion membrane 
on the central ulcer, may impends for 
perforation too. The patient was 
discharged from hospital.  
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Day by day (on October), the 
size of the thin cornea becomes small 
that was covered by the thin amnion. 
On November – December 2006 (two 
months later) we did not see her again. 
We were very happy and thought that 
MLAMT can reduce progressivity of 
the Mooren’s ulcer.  
On January 2007, she came 
with impending perforation on the 
margin ulcer and the ulcer was 
extended to paracentral and superior 
corneal region, about 7x3 mm. (see 
photos on Januari 2007). Because of 
that, we suggested doing MLAMT and 
partial Bare Sclera immediately again, 
the patient agrees spontaneously. On 
the ninth day after the operation, 
epitelialization begins, and completes 
on the 14
th
 day. The duration of the 
epitelialization for this operation need 
longer than previous operation, and we 
plan to discharge her from hospital.  
But one day after that (about 2 
weeks after the second surgery), we 
found a new rounded ulcer on the 
inferior cornea and we decided to 
perform an operation the next day. We 
performed total Bare Sclera and 
MLAMT with three days patching 
again. MLAMT and total Bare Sclera 
can make complete epitelialization on 
the 9
th
 day after the operation, fast from 
second operation, but still have 
impending perforation of the cornea. 
(See photos on February 2007) In this 
time, we followed with systemic 
corticosteroid, but we still did not give 
topical cyclosporine, because no 
available preparation. The patient 
discharged of hospitalization, and 
visual acuity on the right eye was 
20/40.   
Until now, she never came 
again, maybe afraid to face an 
operation again, but we hope, that the 
ulcer doesn’t perforate yet and the eye 
still on the same condition.  
Surgery Procedure 
Conjunctival resection is useful 
in treating Mooren’s ulcer; it can be 
perform under general, subconjunctival 
or retrobulbar anesthesia. In this case 
we had done under general anesthesia 
and povidone iodine solution for 
disinfectant. All of the conjunctival 
flap on the corneal surface will be 
removed and performed conjunctival 
excision (bare sclera) for extended 3 to 
4 mm posterior to the corneascleral 
limbus, and parallel to the ulcer. After 
removed the adjacent conjunctiva, we 
could see the ulcer size with thin 
cornea and excavation, from peripheral 
to parasentral corneal. The affected 
tissues were excised and repeated the 
povidone iodine irrigation again.  
The amniotic membrane was 
peeled from its holding gauze, cut with 
the same size of the ulcer excavation 
that near from the normal cornea, and 
with epithelial side up placed on the 
stromal ulcer, one by one layer (two 
layers) for filling-in, and two layers for 
cover all size of the ulcer. After that, all 
corneal surface and surrounding, about 
two millimeter of adjacent conjunctiva 
were patched with three layers of 
amniotic membrane. All of the 
amniotic membrane layers sutured with 
interrupted 8-0 silk on the conjunctiva 
at 8 positions. Antibiotic eye drop 
applied, closed and patching the eye. 
One day after surgery, the eye may 
open only 1 mm for eye drop and we 
continue this condition until 3 days. On 
the day 3
rd
, we will measure the 
apparent epithelialization and observe, 
when the epithelialization was 
completes (negative fluorescent 
staining). The sutures in the amniotic 
membrane to conjunctiva were 
removed about 2 week’s period. 
The second surgery is similar 
with the first surgery; we performed 
conjunctival resection parallel with the 
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new ulcer on the superior and more 
central cornea and performed 
MLAMT. The remnant Amnion 
membrane on the surface ulcer after the 
first surgery didn’t removed, because 
the attachment was good. After 
surgery, we followed with three days 
patching.The method of the third 
surgery is similar too, but we 
performed total Bare Sclera with 
MLAMT and three days patching.  
 
Discussion 
We had been reported one 
patient with recurrent Mooren’s ulcer 
on the RE with VA 20/25, and pthysis 
on the LE without clear history, that 
may be the  malignant type of 
Mooren’s ulcer, because it had been 
grown when she was young, recurrent 
and responded poorly to conventional 
therapy. And now, unfortunately, she 
had conjunctival flap for prevent 
perforated of the thin cornea, and on 
the margin of the flap conjunctiva was 
seen the deep ulcer. The conjunctival 
flap can provoke progression of the 
ulcer, because it’s increasing 
autoimmune response, lymphocytes, 
plasma cells, macrophages by vascular, 
it’s can cause increased production of 
collagenolytic enzyme and lysis the 
healthy cornea. Chen KH et al 
(2003),
(30)
 reported the relapsing 
Mooren’s ulcer after AMT combined 
with conjunctival autografting. On this 
condition, she didn’t agree to get 
surgery; we only gave antibiotic eye 
drops, lubrication/tear film substitution, 
and topical cycloplegic, topical and 
systemic anticollagenases, systemic 
and topical anti glaucoma and 
multivitamins. We didn’t give topical 
corticosteroid; because the corneal 
impending perforation and high risky 
case, and cyclosporine preparation 
didn’t available.  
One month later (See photos on 
September 2006), she admitted to our 
hospital with worse condition, the 
recurrent Mooren’s ulcer was deeper, 
extended to paracentral cornea and she 
was agreed for the operation. We 
performed partial Bare Sclera and 
MLAMT with three days patching, 
under general anesthesia. Conjunctival 
resection is indicated in treating 
peripheral corneal ulcers of 
autoimmune origin that is unresponsive 
to medical intervention, and it’s useful 
in treating Mooren’s ulcer,(1,20) and by 
using MLAMT the corneal wound 
healing become faster. On the ninth 
day after surgery the epitelialization 
was completes (fluorescents staining 
was negative). 
For one month, she regularly 
control, but 2 months later, she came 
with impending perforation on the 
margin ulcer and the ulcer was 
extended to paracentral and superior 
corneal region, about 7x3 mm. (see 
photos on January 2007). Because of 
that, we suggested doing MLAMT and 
partial Bare Sclera immediately again. 
The epithelialization was completes on 
the 14
th
 day. The duration of the 
epithelialization for this operation need 
longer than previous operation.  
But one day after that (about 2 
weeks after the second surgery), we 
found a new rounded ulcer on the 
inferior cornea and we decided to 
perform an operation the next day. We 
performed total Bare Sclera and 
MLAMT with three days patching 
again. MLAMT and total Bare Sclera 
can make complete epithelialization on 
the 9
th
 day after the operation, fast from 
second operation, but still have 
impending perforation of the cornea. 
(See photos on February 2007) In this 
time, we followed with systemic 
corticosteroid, but we still did not give 
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topical cyclosporine, because no 
available preparation. The patient 
discharged of hospitalization, and the 
uncorrected visual acuity on the right 
eye was 20/40.  
The treatment of Mooren’s 
ulcer is difficult and frequently 
unsatisfactory,
(2)
 but for this patient 
may be better if the surgery followed 
by application of topical and systemic 
immunosuppressant.
(1) 
The recurrence 
of Mooren’s ulcer still unclear, and 
possibility the immunology process, 
tissue-fixed immunoglobins and 
complement in both the adjacent 
conjunctiva and in the corneal 
epithelial basement membrane.
(2) 
For 
this reason perhaps, is impossible to 
prevent the recurrence of Mooren’s 
ulcer.   
Until now, she never came, maybe 
afraid to face an operation again, but 
we hope, that the ulcer does not 
perforate and the eye still on the same 
condition.  
 
Conclusions 
Although only one case is 
reported, in fact that MLAMT can 
reduce the time of recurrence of 
Mooren’s ulcer, but cannot stop the 
progressivity. We can do MLAMT 
more than once and we must think and 
do more discussions whether MLAMT 
can stop the Mooren’s ulcer 
progressivity to prevent severe visual 
morbidity. Total conjunctiva resection 
(Bare Sclera) probably gives better 
result than partial resection for 
Mooren’s ulcer.  
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Patient Photos  
Identity  : Female, 44 yo. 
Diagnosis  : Recurrent Mooren’s Ulcer’s 
On August 06 
      A                  B 
 
 
 
 
 
                                                             
C                                                                            D 
 
 
 
 
 
 
1A: Recurrent Mooren’s ulcer with conjunctival flap on the temporal side RE. 
IB: Excavatio near to the conj flap. IC: the quite ulcer on the nasal side RE. ID: 
The thinner part of the corneal.   
On September 2006 
 
2A                                                                             2B                           
    
 
 
 
2A-2B: The active ulcer on the margin of the conjunctiva flap with excavation 
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2C      2D                                  
 
 
 
 
2E     2F 
 
 
 
   
2D-F: 1
st
 bare sclera with MLAMT for filling, graft of ulcer, and patching all of    
the corneal surface and suture on the conjunctiva      
3A        3B 
 
 
     
 
 
  3C        3D 
 
 
 
 
3A - 3B: Post 1
st
 operation MLAMT & Bare Sclera with epithelialization, the 
AM sutured on the conjunctiva circumferentialy. 3C -3D: The thin AM layer can 
cover the surface of the thinner cornea on the surface of the ulcer 
On Oktober- November 2006 
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4A                  4B               4C    
 
 
 
 
 
4D        4E            4F 
 
 
 
 
 
 
 
 
 
 
 
4A-F: Complete epithelization on the surface of the ulcer.     
On January 2007 
 
 5A                   5B  
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5A - 5B: The impending perforation ulcer and extended to the paracentral and 
superior cornea.  
On February 2007 (after the 2
nd
 MLAMT and Partial Bare Sclera) 
6A          6B           6C 
 
 
 
 
 
 
6A-C: MLAMT and Bare sclera can make epithelialization and covered the 
thinner corneal 
On February 2007 
 
7A                7B     7C  
 
 
 
 
 
 
7A-C: Ulcer was extended to the inferior cornea 
On February 2007   
 8A       8B 
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8C       8D 
  
 
 
 
 
8E       8F 
 
 
 
   
     8A-F: After 3
rd
 MLAMT and Bare Sclera, the impending perforation cornea 
still present, although AM can make complete epithelialization on the 9
th
 day. 
  
On March 2007 
9A               9B  
      
 
 
 
9C               9D  
 
 
 
    
      9A-D: The last condition, with complete epithelialization 
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